Rosuvastatin coprescription with canagliflozin tied to Statin toxicity

Written By : Hina Zahid

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-08-04 07:00 GMT | Update On 2023-10-17 10:35 GMT

Researchers have found in a case study that Coprescription of rosuvastatin and canagliflozin may lead to Statin toxicity.

Physicians should be aware that canagliflozin could cause rosuvastatin toxicity when the two drugs are prescribed together. This is an important finding because these drugs are taken by millions of patients worldwide and are increasingly prescribed together. The first report of an interaction between these two drugs is published in Annals of Internal Medicine.

Rosuvastatin belongs to a group of medicines called HMG-CoA reductase inhibitors, or statins. It works by blocking an enzyme that is needed by the body to make cholesterol, so this reduces the amount of cholesterol in the blood.

Rosuvastatin is a commonly prescribed statin and canagliflozin is one of a newer class of diabetes drugs, the sodium-glucose cotransporter-2 (SGLT2) inhibitors. It is common for patients with diabetes to also take a statin. In fact, the American College of Cardiology currently recommends adding an SGLT2 inhibitor, such as canagliflozin, to the regimens of patients with diabetes and cardiovascular disease.

The major reason for statin discontinuation is because of the development of statin-associated muscle symptoms, but a range of other statin-induced side effects also exist.

Very rarely, statins can cause life-threatening muscle damage called rhabdomyolysis. Rhabdomyolysis can cause severe muscle pain, liver damage, kidney failure and death.

Researchers from the University of Toronto describe the case of a patient who was hospitalized with severe rosuvastatin toxicity (manifesting as muscle damage and inability to walk) 2 weeks after starting canagliflozin. Although she had taken rosuvastatin uneventfully for more than 5 years, her blood rosuvastatin concentration when she arrived at the hospital was 15 times higher than expected for her dose. The authors speculate that canagliflozin caused rosuvastatin toxicity by increasing rosuvastatin absorption, and by reducing its elimination by the liver and kidney. The authors encourage clinicians to remain vigilant for features of myotoxicity when canagliflozin and rosuvastatin are co-prescribed.

For more details click on the link: https://www.acpjournals.org/doi/10.7326/L20-0549

Article Source : Annals of Internal Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Beta-blockers Reduce Death, MI, Heart Failure 25% in Mildly Reduced LVEF: Latest Meta-Analysis Presented at ESC Congress 2025

2025-09-12 03:30 GMT

Rosuvastatin coprescription with canagliflozin tied to Statin toxicity

Similar News

Beta-blockers Reduce Death, MI, Heart Failure 25% in Mildly Reduced LVEF: Latest Meta-Analysis Presented at ESC Congress 2025

Gestational Diabetes Tied to Long-Term Thyroid Disorders, Study Finds

At-home blood pressure cuffs-and reminders to use them-key to blood pressure control: JAMA

Greater Kidney Complications in Patients Diagnosed with Type 2 Diabetes Before 40: Study Finds

Aronia Extract Improves Cardiovascular Health and Reduces Inflammation in Elderly with Metabolic syndrome: Study

Psychological Distress Common in Youth with Hip Pain: Study

Female Veterans with Lupus or Rheumatoid Arthritis Have Higher Pregnancy Risks, Finds Study

Young-Onset Diabetes Tied to Beta Cell Deficiency, Not Obesity: PHENOEINDY-2 Study